SG293

About Sana Biotechnology

Sana Biotechnology is at the forefront of developing a new class of engineered cell therapies designed to be broadly accessible. The company is advancing a pipeline of innovative candidates, including stem cell-derived pancreatic islets for type 1 diabetes and in vivo CAR T therapies for B-cell malignancies and autoimmune disorders. With a seasoned leadership team and a focus on overcoming key challenges in cell therapy like immune rejection and scalable manufacturing, Sana aims to deliver durable, one-time cures for a wide range of serious diseases.

Therapeutic Areas